Sonic Healthcare has warned that its full year earnings will be up to four per cent below its guidance due to weakness in the Australian pathology market.
The medical diagnostics company says its 2014/15 earnings before interest, tax, depreciation and amortisation (EBITDA) will be three or four per cent below guidance at around $730 million.
It blamed lower volumes in the Australian pathology market due to changes to the Medicare Benefits Schedule and higher infrastructure costs.
However, Sonic expects its 2015/16 EBITDA to be between $850 and $875 million, which would be about 20 per cent higher than the 2014/15 result.
Share
